Compare Impinj Inc (PI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs TransMedics Group Inc — how do they compare? Impinj Inc trades at $165.2 (market cap $5.26B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Impinj Inc is the larger of the two by market cap, and Impinj Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| PI | TMDX | |
|---|---|---|
Market Cap | $5.26B | $3.06B |
Sector | Technology | Technology |
52-Week High | $241.91 | $150.42 |
52-Week Low | $91.34 | $61.99 |
Enterprise Value | $5.39B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $171.90, down 0.27% on the day, with strong technical momentum indicated by bullish moving averages and recent golden cross formation. The company reported record Q2 2026 revenue and earnings beats, though maintains negative net income margins. Analyst consensus remains strongly bullish with 73% buy ratings and a $194.50 price target representing 13% upside potential from current levels.
While Impinj shows promising revenue growth and technical strength, investors face risks from negative profitability metrics and high valuation multiples. The company's specialized RAIN RFID technology positions it for logistics market expansion, but execution risks and competitive pressures require careful monitoring. Institutional buying activity suggests confidence in long-term prospects despite recent insider selling.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
